“We are excited to have successfully closed this transaction. With Aterian’s investment in people, technology and processes, CPL is equipped and ready to enter its next phase of growth and to drive industry transformation by providing further value to customers,” said the Aterian team. “With Aterian’s backing, we are laser focused on innovation, growth and delighting our customers to further expand our unmatched position in the non-sterile liquid and topical drug products space,” said Jan Sahai, CEO of CPL. “This collaboration undoubtedly strengthens our positioning in serving our customers and being the trusted partner to pharmaceutical companies around the world.” Jay Taunk, Principal at Aterian, added, “CPL represents Aterian’s thirteenth investment in the life sciences, personal care and nutrition segments. We are thrilled to support CPL and look forward to working with the management team to continue the Company’s growth trajectory.” About CPL CPL is a leading CDMO that provides development, manufacturing, packaging, and testing of non-sterile liquid and semi-solid pharmaceutical prescription and regulated OTC products for markets worldwide. For more information, please visit www.cplltd.com. About Aterian Investment Partners Aterian Investment Partners is a private equity firm that invests in industry-leading, middle market businesses. In collaboration with management, Aterian holistically supports organizations with a focus on strategic positioning, people, processes, equipment, technology, and product innovation, among others. With offices in New York and Miami, Aterian has raised cumulative equity commitments of more than $2.0 billion since its founding in 2009. For more information, please visit www.aterianpartners.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240606726772/en/ Contacts Media: Alex Goss | Stanton PR & Marketing [email protected] 646-502-3576 #distro
Subscribe
Login
0 Comments
